In particular, as recently reported [13], SerpinB3 was able to influence the hepatic levels of Galectin 3, CD9 and TREM2, typical markers of NAMs, a population of hepatic macrophages emerging in progressive NAFLD-NASH and strictly associated with severity of steatosis, inflammation as well as fibrosis [50]. Here, LGALS3 is linked to metabolic dysfunction-associated steatotic liver disease.